Lung cancers bearing oncogenically-mutated EGFR represent a significant fraction of lung adenocarcinomas (LUADs) for which EGFR-targeting tyrosine kinase inhibitors (TKIs) provide a highly effective t
Abstract. Leveraging ferroptosis as a cancer therapy has faced challenges due to the limited bioavailability and systemic toxicities of small molecule ferroptosis modulators. Small molecule inhibitors
We have examined the microRNA expression in 154 lung adenocarcinoma samples and 20 paired normal lung tissue samples and investigated the microRNA expression to clinical variables, EGFR- and KRAS- mut
Gene expression of a 3D model for the treatment of EGFR mutated lung tumors (HCC827 cell line, sensitive to gefitinib, and A549 cells, insensitive to gefitinib) was analysed and compared to the same t
